Background Intensified antibiotic treatment might improve the outcome of tuberculous
meningitis. We assessed pharmacokinetics, safety, and survival benefit of several treatment …

Introduction: Type 2 Diabetes (T2D) is a major health problem worldwide. This metabolic
disease is indicated by high blood glucose levels due to insufficient insulin production by the …

Objectives To review the current knowledge about tuberculosis (TB) and diabetes, assessing
the implication of the global increase of diabetes for TB control and patient care. Methods …

Diabetes triples the risk for active tuberculosis, thus the increasing burden of type 2 diabetes
will help to sustain the present tuberculosis epidemic. Recommendations have been made …

Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear. …

Background A 9-month regimen of isoniazid can prevent active tuberculosis in persons with
latent tuberculosis infection. However, the regimen has been associated with poor …

Background . Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB) and is
associated with a slower response to TB treatment and a higher mortality rate. Because lower …

Rifampin is a key drug for tuberculosis (TB) treatment. The available data suggest that the
currently applied 10-mg/kg of body weight dose of rifampin may be too low and that increasing …

Background The treatment of latent infection with Mycobacterium tuberculosis is important in
children because of their vulnerability to life-threatening forms of tuberculosis disease. The …

Altered pharmacokinetics of antituberculosis drugs may contribute to an increased risk of
tuberculosis treatment failure for diabetic patients. We previously found that rifampin exposure …